(Q40406471)

20 September 2017

1 reference

title

New thrombolytic agents and strategies (English)

1 reference

20 September 2017

1 reference

Collen D

1

1 reference

20 September 2017

Lijnen HR

series ordinal

2

1 reference

20 September 2017

publication date

1 June 1995

1 reference

Best Practice and Research: Clinical Haematology

20 September 2017

published in

1 reference

20 September 2017

volume

8

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

425-435

1 reference

Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Conjunctive antithrombotic and thrombolytic therapy for coronary-artery occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Innovative approaches to plasminogen activator therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Prevention of thrombosis and rethrombosis. New approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

High yield production and purification of recombinant staphylokinase for thrombolytic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980277-X

7 January 2021

10.1016/S0950-3536(05)80277-X

Identifiers

DOI

1 reference

20 September 2017

1 reference